Cite
HARVARD Citation
Maulik, N. et al. (2016). Reply to the letter "thioredoxin-1 (Trx1) engineered mesenchymal stem cell therapy is a promising feasible therapeutic approach for myocardial infarction". International journal of cardiology. pp. 277-278. [Online].